MDXL — Medixall Income Statement
0.000.00%
Last trade - 00:00- $0.80m
- $5.54m
- $0.31m
- 45
- 24
- 82
- 48
Annual income statement for Medixall, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.003 | 0 | 0.015 | 0.059 | 0.309 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.073 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.42 | 5.93 | 6.22 | 6.89 | 4.87 |
| Operating Profit | -3.42 | -5.93 | -6.2 | -6.83 | -4.56 |
| Net Income Before Taxes | -3.42 | -5.93 | -6.2 | -6.83 | -4.56 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.42 | -5.93 | -6.2 | -6.83 | -4.56 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.42 | -5.93 | -6.2 | -6.83 | -4.56 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.42 | -5.97 | -6.45 | -7.14 | -4.88 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.046 | -0.066 | -0.063 | -0.059 | -0.038 |